10x Genomics, Inc. — Form 8-K Summary
Business context and reporting period
10x Genomics, Inc. filed a Current Report on Form 8-K dated November 2, 2023, under Item 2.02 to announce financial results for the quarter ended September 30, 2023. The filing references a related press release as Exhibit 99.1, but the press release text and its financial details are not included in the provided filing content.
Financial metrics
The provided filing text does not provide clear values for revenue, net income or loss, cash flow, gross or operating margins, debt, cash, liquidity, or other financial metrics.
Changes versus the prior comparable period
The filing does not include financial data or discussion sufficient to identify changes versus the prior-year or prior-quarter comparable period.
Guidance, outlook, risks, and unusual items
The filing does not provide guidance, outlook commentary, risk updates, contingencies, or unusual-item disclosures. It only furnishes the announcement of quarterly results and identifies the related press release as Exhibit 99.1.
Investor verification items
- Review Exhibit 99.1 for quarterly revenue, profitability, cash flow, balance-sheet, and liquidity metrics.
- Verify management’s guidance, outlook, operating commentary, and discussion of risks or unusual items in the referenced press release.
- Compare the September 30, 2023 results with the prior comparable period using the company’s full earnings release or subsequent periodic filing.
- Note that the Item 2.02 information and attached press release are furnished, not filed, for purposes of Section 18 of the Exchange Act, and are not incorporated by reference except where expressly stated.